CRNX - Crinetics Pharmaceuticals Inc. (CRNX) Q1 2024 Earnings Call Transcript
2024-05-11 10:09:07 ET
Crinetics Pharmaceuticals, Inc. (CRNX)
Q1 2024 Earnings Conference Call
May 9, 2024 4:30 PM ET
Company Participants
Corey Davis - LifeSci Advisors
Scott Struthers - Founder and Chief Executive Officer
Alan Krasner - Chief Endocrinologist
Marc Wilson - Chief Financial Officer
Jim Hassard - Chief Commercial Officer
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Jessica Fye - JPMorgan
Cory Jubinville - LifeSci Capital
Joseph Schwartz - Leerink Partners
Jon Wolleben - Citizens JMP
Leland Gershell - Oppenheimer
Douglas Tsao - H.C. Wainwright
Catherine Novack - Jones Research
Michael Riad - Morgan Stanley
Charles Moore - Baird
David Lebowitz - Citi
Dennis Ding - Jefferies
Presentation
Operator
Welcome to the Crinetics Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session.
I will now turn the call over to Corey Davis of LifeSci Advisors. Please go ahead.
Corey Davis
Thank you, Alan. Hello, everyone, and welcome to Crinetics earnings call. Joining me today are Dr. Scott Struthers, Founder and Chief Executive Officer; Dr. Alan Krasner, Chief Endocrinologist; and Marc Wilson, Chief Financial Officer. Also joining us for the Q&A portion of the call are Dr. Dana Pizzuti, Chief Medical and Development Officer; and Jim Hassard, Chief Commercial Officer.
A press release announcing the first quarter 2024 financial results was issued today and is also available on the Crinetics corporate website. As a reminder, we'll be making forward-looking statements and I invite you to learn about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's businesses.
These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Crinetics SEC filings, including its annual report on Form 10-K. I'd also like to specify that the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 9, 2024. Crinetics takes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.
With that, I'll hand it over to Scott. Go ahead.
Scott Struthers
Thank you, Corey. Good afternoon, everyone, and thank you for joining us on our first quarter 2024 results call....
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript